Innate Pharma (IPHYF) Receivables - Net (2017 - 2025)

Innate Pharma's Receivables - Net history spans 9 years, with the latest figure at $14.7 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 177.17% year-over-year to $14.7 million; the TTM value through Dec 2025 reached $14.7 million, up 177.17%, while the annual FY2025 figure was $14.7 million, 173.65% up from the prior year.
  • Receivables - Net reached $14.7 million in Q4 2025 per IPHYF's latest filing, up from $5.3 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $71.1 million in Q4 2023 to a low of $5.3 million in Q4 2024.
  • Average Receivables - Net over 5 years is $37.1 million, with a median of $39.1 million recorded in 2022.
  • Peak YoY movement for Receivables - Net: plummeted 92.53% in 2024, then surged 177.17% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $55.2 million in 2021, then decreased by 29.11% to $39.1 million in 2022, then surged by 81.82% to $71.1 million in 2023, then tumbled by 92.53% to $5.3 million in 2024, then surged by 177.17% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Receivables - Net are $14.7 million (Q4 2025), $5.3 million (Q4 2024), and $71.1 million (Q4 2023).